PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 368.80
Bid: 368.40
Ask: 368.80
Change: 1.40 (0.38%)
Spread: 0.40 (0.109%)
Open: 360.20
High: 369.20
Low: 360.20
Prev. Close: 367.40
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-Close Trading Statement

29 Sep 2017 07:00

RNS Number : 1742S
QinetiQ Group plc
29 September 2017
 

News release

 

QinetiQ Group plc

Pre Close Trading Update

29 September 2017

QinetiQ today issues a short trading update before entering its closed period for the half year ending 30 September 2017.

Outlook

Trading has been in line with expectations and the outlook for overall Group performance this financial year is unchanged.

EMEA Services

The EMEA Services division started the year in a strong position. Following stronger order intake in the second quarter, FY18 revenue under contract is as expected at this stage in the financial year. We reiterate our guidance for modest growth in revenue in FY18.

Global Products

The Group's Global Products division has been trading in line with expectations during the first half of the year. As a result of its contracted orders and pipeline of opportunities, as well as the anticipated full year contribution from QinetiQ Target Systems, the division is expected to grow in FY18.

Strategic progress

QinetiQ continues to make progress towards becoming a more customer focused and international company. In both the UK and internationally we are particularly well placed to help customers meet the challenges of increasing capabilities while addressing budgetary concerns, and this is reflected in recent key contract awards.

In our UK home market, as part of our strategy to modernise test and evaluation, we secured:

·

An £8m order from the UK Ministry of Defence (MOD) to provide naval combat systems expertise for Type 26 Global Combat Ship added to the £110m 11-year Naval Combat System Integration Support Services (NCSISS) contract agreed with the MOD this time last year

·

An order from Boeing, worth approximately £25m, to continue to deliver wind tunnel testing for their commercial aircraft development until 2024

 

In our US and Australian home markets, as part of our strategy to build an international company, we were awarded:

 

·

A significant order for aircraft launch and recovery equipment for the new class of US Navy aircraft carriers

·

An AU$8m order to manage mine warfare maintenance facilities at HMAS Waterhen for the Australian Department of Defence

 

 

ENDS

 

 

Notes for Editors:

 

For further information please contact:

 

David Bishop, Group Director Investor Relations and Communications

+44 (0) 7920 108675

Investor Relations

Ian Brown, Group Head of Investor Relations

+44 (0) 7908 251123

Media Relations

QinetiQ press office

+44 (0) 1252 393500

 

QinetiQ's interim results for the half year ending 30 September 2017 will be announced on 16 November 2017.

 

Listed on the London Stock Exchange (LSE: QQ.L), QinetiQ is a leading science and engineering company operating primarily in the defence, security and aerospace markets. Our customers are predominantly government organisations including defence departments, as well as international customers in other targeted sectors.

 

·

Visit our website www.QinetiQ.com

·

Follow us on LinkedIn and Twitter @QinetiQ

·

Visit our blog www.QinetiQ-blogs.com

 

 

 

Disclaimer

 

This document contains certain forward-looking statements relating to the business, strategy, financial performance and results of the Company and/or the industry in which it operates. Actual results, levels of activity, performance, achievements and events are most likely to vary materially from those implied by the forward-looking statements. The forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words 'believes',' expects', 'predicts', 'intends', 'projects', 'plans', 'estimates', 'aims', 'foresees', 'anticipates', 'targets', 'goals', 'due', 'could', 'may', 'should', 'potential', 'likely' and similar expressions, although these words are not the exclusive means of doing so. These forward-looking statements include, without limitation, statements regarding the Company's future financial position, income growth, impairment charges, business strategy, projected levels of growth in the relevant markets, projected costs, estimates of capital expenditures, and plans and objectives for future operations. Forward-looking statements contained in this announcement regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Nothing in this document should be regarded as a profit forecast.

The forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources, contained in this announcement are solely opinions and forecasts which are uncertain and subject to risks. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to be correct. Actual results may differ materially from those expressed or implied by these forward-looking statements. A number of factors could cause actual events to differ significantly and these are set out in the principal risks and uncertainties section of this document. Most of these factors are difficult to predict accurately and are generally beyond the control of the Company. Any forward-looking statements made by, or on behalf of, the Company speak only as of the date they are made. Save as required by law, the Company will not publicly release the results of any revisions to any forward-looking statements in this document that may occur due to any change in the Directors' expectations or to reflect events or circumstances after the date of this document.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFVLAFITFID
Date   Source Headline
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.